Printer Friendly

Innovus Partner Luminarie Receives New Zealand Approval for Zestra for Female Sexual Arousal Disorder as a Medical Device I.

M2 PHARMA-September 22, 2017-Innovus Partner Luminarie Receives New Zealand Approval for Zestra for Female Sexual Arousal Disorder as a Medical Device I

(C)2017 M2 COMMUNICATIONS

- US-based specialty pharmaceutical company Innovus Pharmaceuticals, Inc.'s (OTCQB Venture Market: INNV) partner, Luminarie Pty Ltd, has received approval to commercialise Innovus Pharma's product Zestra as a Medical Device I from New Zealand's FDA equivalent Medicines and Medical Devices Safety Authority for the treatment of Female Sexual Arousal Disorder, the company said.

Innovus Pharma signed in May 2017 an exclusive license and distribution agreement with Luminarie, a company based in Australia, for the commercialization of Zestra for Female Sexual Arousal Disorder and Zestra Glide for female lubrication in the Australia, New Zealand and the Philippines.

Besides, Luminarie, Zestra is currently exclusively partnered with Orimed Pharma, the OTC subsidiary of Jamp Pharma in Canada, Densmore in France and Belgium, DanaLife ApS in select European markets including Denmark, Sothema Laboratories for the Middle East and North Africa, Elis Pharmaceuticals in Turkey and certain select markets including Lebanon, BioTask in Malaysia and J and H Co. LTD in South Korea, and non-exclusively to PT Resources in Hong Kong and certain select Asian markets.

Zestra is currently approved to be commercialized in 36 countries in the world namely, in Canada, the 28 countries of the European Union, Australia, New Zealand, India, Hong Kong, the United Arab Emirates, South Korea and Morocco.

Innovus Pharma currently generates revenues from various markets for Zestra, including Canada, Morocco, certain European countries, South Korea and Hong Kong in addition to the United States as its biggest market.

Zestra is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women.

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialisation, licensing and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:8NEWZ
Date:Sep 22, 2017
Words:350
Previous Article:Shady Grove Fertility Simplifies Egg Donation, Donor Selection with New Portal.
Next Article:e-Pharma Market to Reach USD 109.2bn by 2025, Grand View Research Forecasts.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters